



ASIAN INVESTMENT SERIES 2018

13 March 2018 KPMG Hong Kong 15-16 March 2018 KPMG Shanghai

HONG KONG BIOTECH
INVEST & PARTNERING

AUSTRALIA-CHINA BIOTECH
INVEST & PARTNERING



Cancer Trials
Australia

Cancer Trials Australia

Company Description

Cancer Trials Australia (CTA) is a highly effective member based clinical trial network and site service organization, which has provided clinical trial administrative support to its members for over 20 years. Since its inception in 1993, CTA has administered the start-up and management of over 1,200 oncology clinical trials, sponsored by over 230 different organizations that have recruited in excess of 7,000 patients.

CTA administers oncology clinical trials that range from first-time-in-human trials to large scale Phase III trials. With 24 members throughout Victoria, NSW, South Australia and Western Australia, collaboration across these members provides a great opportunity for sponsors to conduct multi-site clinical trials, accruing significant patient numbers quickly, despite Australia's relatively small population.

Australia is recognized as a hub for early phase clinical trials and many international biotech and pharmaceutical companies continue to launch early phase trials in Australia. CTA has an established Phase I Group and administers >50% of all Phase 1 oncology trials within Australia. This unique clinical group includes key opinion leaders who can review pre-clinical trial data and quickly offer impartial recommendations regarding study design, strategy, and relevant submissions. CTA is capable of facilitating Phase I trials across all tumour types, in tumour-specific or molecular-target-specific studies. We are conveniently situated in the state-of-the-art Victorian Comprehensive Cancer Centre in Melbourne.

Pipeline and Developments

We currently support over 500 oncology clinical trials across our Members, with ~200 new trial submissions annually.

What we are looking for:

Building on the recognition of Australia as a hub for early phase clinical trials and our experience supporting Asian biotech companies to conduct oncology clinical trials in Australia, we seek to speak with biotech companies as they approach the clinic with their oncology therapeutics, or as they pursue expansion of their current trials to incorporate Australia.

Contact:

Name: Kurt Lackovic

Position: Chief Executive Officer

Company: Cancer Trials Australia

Address: Level 10, VCCC building, 305 Grattan St, Melbourne, 3000

Website: www.cancertrialsaustralia.com

Phone: +61 (0)3 8559 5189

Email: kurt.lackovic@ctaust.org

For more information, please visit www.australiabiotechinvest.com.au



Follow us for the latest event update #AusBioInv